Product launch drives 78 per cent growth at Oxfordshire’s Eden Research

Biopesticide developer Eden Research has seen growth of 78 per cent for the year ended 31 December 2023, according to newly posted preliminary results.

Based at Milton Park in Oxfordshire, Eden posted annual revenues of £3.2 million – up from £1.8 million a year prior – while cutting its operating losses by 27 per cent.

The past year has seen the firm launch a new seed treatment product, Ecovelex, for which it’s secured temporary approval in Italy for use in the 2024 growing season.

Eden also gained several new regulatory approvals in the US for its flagship biopesticides, Mevalone and Cedroz.

Meanwhile, the firm has conducted ‘promising field trials’ for its upcoming insecticide. Discussions are ongoing with potential commercial partners.

Lykele van der Broek, chair of Eden Research, said: “Eden made substantial progress against its strategic goals in 2023, including the launch of our innovative seed treatment product, Ecovelex.

“Developed in less than four years, this is a groundbreaking moment for the business and a testament to the strength of Eden’s capabilities and commercial relationships.

“It’s contributed to our revenue growth over the year, which we look forward to building on in the future as we focus on expanding regulatory approvals and authorisations in our target geographies – and the development of other product lines, including our bioinsecticide product.”